P01.8 Remote effects of botulinum toxin therapy in hyperhydrosis treatment

2006 ◽  
Vol 117 ◽  
pp. 124
Author(s):  
E. Milano ◽  
M. Coletti Moja ◽  
F. Celotto ◽  
C. Favarato ◽  
A. Mauro ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Therapy

Botulinum Toxin Therapy

1991 ◽  
Vol 9 (1) ◽  
pp. 205-224 ◽  
Author(s):  
Peter J. Savino ◽  
Marlon Maus
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Therapy

scholarly journals Long-term Botulinum toxin therapy for focal hand dystonia and reasons for discontinuation

2013 ◽  
Vol 11 (8) ◽  
pp. 657
Author(s):  
Zoltan Mari ◽  
Gopiga Thanabalasundaram ◽  
Eric Farbman ◽  
Barbara Karp ◽  
Mark Hallett
Keyword(s):  
Botulinum Toxin ◽  
Focal Hand Dystonia ◽  
Botulinum Toxin Therapy ◽  
Hand Dystonia

Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders

2008 ◽  
Vol 29 (5) ◽  
pp. 333-338 ◽  
Author(s):  
Pasquale Capaccio ◽  
Sara Torretta ◽  
Maurizio Osio ◽  
Davide Minorati ◽  
Francesco Ottaviani ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Therapy

scholarly journals Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis

2013 ◽  
Vol 15 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Gael J. Yonnet ◽  
Anette S. Fjeldstad ◽  
Noel G. Carlson ◽  
John W. Rose
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Botulinum Toxin ◽  
Urinary Tract ◽  
Detrusor Overactivity ◽  
Anticholinergic Drugs ◽  
Neurogenic Detrusor Overactivity ◽  
Botulinum Toxin Therapy ◽  
Tract Infections

Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a second-line option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time.

Quantitative Electromyographic Analysis of Changes in Muscle Activity Following Botulinum Toxin Therapy for Cervical Dystonia

1993 ◽  
Vol 16 (3) ◽  
pp. 205-210 ◽  
Author(s):  
Aron S. Buchman ◽  
Cynthia L. Cornelia ◽  
Glenn T. Stebbins ◽  
Caroline M. Tanner ◽  
Christopher G. Goetz
Keyword(s):  
Botulinum Toxin ◽  
Muscle Activity ◽  
Cervical Dystonia ◽  
Botulinum Toxin Therapy ◽  
Electromyographic Analysis

scholarly journals Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing

2014 ◽  
Vol 4 (0) ◽  
pp. 273 ◽  
Author(s):  
Virgilio Gerald H. Evidente ◽  
Eric J. Pappert
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin Therapy
Sign in / Sign up

Export Citation Format

Share Document